| Literature DB >> 27229934 |
Stefano Frara1, Filippo Maffezzoni1, Gherardo Mazziotti2, Andrea Giustina3.
Abstract
Diabetes mellitus is a frequent complication of acromegaly, a disease characterized by chronic hypersecretion of growth hormone (GH) by a pituitary adenoma. Diabetes occurs commonly but not only as a consequence of an insulin-resistant state induced by GH excess. The development of diabetes in patients with acromegaly is clinically relevant, since such a complication is thought to increase the already elevated cardiovascular morbidity and mortality risk of the disease. Emerging data suggest that a specific cardiomyopathy can be identified in acromegaly patients with diabetes. Moreover, the presence of diabetes may also influence therapeutic decision making in acromegaly, since traditional and newly developed drugs used in this clinical setting may impact glucose metabolism regardless of control of GH hypersecretion.Entities:
Keywords: acromegaly; cardiovascular risk; diabetes; medical therapy; pegvisomant; somatostatin analogs
Mesh:
Substances:
Year: 2016 PMID: 27229934 DOI: 10.1016/j.tem.2016.04.014
Source DB: PubMed Journal: Trends Endocrinol Metab ISSN: 1043-2760 Impact factor: 12.015